SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

May 30, 2012 07:00 ET

Implant Sciences Adds Middle East to Growing List of QS-B220 Deployments

Corporate and Non-Regulated Government Customers Purchase Benchtop Explosives and Drugs Detection System in Advance of Regulatory Approvals

WILMINGTON, MA--(Marketwire - May 30, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it shipped units of its Quantum Sniffer™ QS-B220 benchtop explosives and narcotics trace detectors. The shipments include a previously announced sale of a distributor demonstration system to China.

Continuing the Company's recent success with non-government users, the latest customer is a corporation in the Middle East that is integrating trace detection into its building security operations. To date, QS-B220s have been sold to customers in Asia, Europe, the Middle East and North America for use in a variety of corporate and government applications including public safety, VIP security, and corporate security.

Since its introduction last year, the QS-B220 has received both CE Certification and ASTM E2520 Certification. The product is currently being evaluated for certification by the U.S. Transportation Security Administration for air cargo screening.

"The QS-B220 is enjoying growing market acceptance due to its ease of use, wide range of explosives and drugs detection capabilities, and freedom from radioactive materials. Currently we are selling to corporate and governmental buyers for non-regulated applications as we move forward with certification processes required to participate in other market segments," stated Implant Sciences' Global Vice President of Sales and Marketing Darryl Jones. "This product greatly expands the global market the Company participates in and we believe it has the potential to far outpace sales of our handheld QS-H150 unit."

About the Quantum Sniffer™ QS-H150

The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220, introduced in May 2011, is a benchtop explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 benchtop explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact